RO-3306 is a CDK1 inhibitor with potential anticancer activity. Treatment of growing AML cells with RO-3306 induced G2/M-phase cell cycle arrest and apoptosis in a dose- and time-dependent manner. RO-3306 downregulated expression of the antiapoptotic proteins Bcl-2 and survivin and blocked p53-mediated induction of p21 and MDM2. RO-3306 actively enhances downstream p53 signaling to promote apoptosis.
Related Products:
Flavopiridol HCL; Flavopiridol; THZ1; BMS-863233 HCl; Dinaciclib; AZD5438; Seliciclib; Palbociclib Isethionate; PHA-793887; Abemaciclib mesylate; Abemaciclib; JNJ-7706621